Skip to main content
Tibet Rhodiola Pharmaceutical Holding Co. logo

Tibet Rhodiola Pharmaceutical Holding Co. — Investor Relations & Filings

Ticker · 600211 ISIN · CNE000000ZW7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600211

About Tibet Rhodiola Pharmaceutical Holding Co.

http://www.xzyy.cn

Tibet Rhodiola Pharmaceutical Holding Co. specializes in the research, development, manufacturing, and distribution of pharmaceutical products, focusing on cardiovascular health and high-altitude medicinal resources. The company’s flagship product is Xinhuo (Recombinant Human B-type Natriuretic Peptide for Injection), a biological drug used in the treatment of acute heart failure. Its portfolio also includes the Nuodiya series, which utilizes Rhodiola extracts to address cardiovascular conditions and hypoxia. The company integrates modern biotechnology with traditional medicinal knowledge to produce a range of chemical drugs, biological agents, and traditional Chinese medicines. Its operations encompass the entire value chain from raw material sourcing to clinical development and commercialization, targeting therapeutic areas such as cardiology and general wellness.

Recent filings

Filing Released Lang Actions
泰和泰律师事务所关于西藏诺迪康药业股份有限公司差异化分红事项的法律意见书
Regulatory Filings Classification · 56% confidence The document is a legal opinion letter (法律意见书) provided by a law firm on the company’s differential dividend plan. It is not a financial report, earnings release, dividend notice, or other specific filing category. It does not contain actual financial statements or serve as an announcement of a report. It is also not a certification or proxy solicitation. Therefore it falls into the fallback category of general regulatory filings (RNS).
2026-05-14 Chinese
西藏诺迪康药业股份有限公司2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 88% confidence The document is a corporate announcement detailing the annual dividend distribution for the 2025 fiscal year, including dividend per share, record date, ex-dividend date, payment date, tax treatment, and implementation procedures. It is not a full financial report but a notice of dividend amount.
2026-05-14 Chinese
西藏诺迪康药业股份有限公司第九届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the first meeting of the ninth board of directors of 西藏诺迪康药业股份有限公司. It details the election and appointment of board members and senior management, including the chairman, vice chairman, general manager, board secretary, deputy general managers, financial director, and R&D center director. It also includes information about the qualifications and backgrounds of these appointees. The document is a formal announcement of changes in the company's board and senior management, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3175 characters, which is relatively short and consistent with an announcement rather than a full report.
2026-05-08 Chinese
董事会战略与ESG委员会实施细则
Governance Information Classification · 95% confidence The document is titled as the implementation rules for the Board's Strategy and ESG Committee of a company. It details the committee's composition, responsibilities, decision-making procedures, and meeting rules. The content focuses on governance structure and ESG (Environmental, Social, and Governance) management practices rather than financial results or announcements. It is a governance-related internal regulation document, not a report of financial performance, audit, or meeting results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2550 characters, which is sufficient for a detailed governance document and not a brief announcement or certification.
2026-05-08 Chinese
西藏诺迪康药业股份有限公司关于回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). It references the initial repurchase plan and provides updates on the repurchase activity as of April 2026. The document is not a full financial report but a specific update on share buyback activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on share repurchase progress, confirming it is not an annual or interim report or other types of filings.
2026-05-07 Chinese
西藏药业2025年度可持续发展报告摘要
Environmental & Social Information Classification · 95% confidence The document is titled as a '可持续发展报告摘要' which translates to 'Sustainability Report Summary'. It references environmental, social, and governance (ESG) topics, including governance structure, stakeholder communication, and ESG materiality assessment. The document covers the period from January 1, 2025, to December 31, 2025, and cites regulatory guidelines related to sustainability reporting. The content focuses on sustainability and ESG factors rather than financial performance or earnings. Given these characteristics, the document fits the category of Environmental & Social Information (SR). The document length is 2362 characters, which is consistent with a summary report rather than a brief announcement or a full annual report. Therefore, the classification is SR with high confidence.
2026-03-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.